Home
  >  
Section 9
  >  
Chapter 8,545

Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model

Winton, E.F.; Srinivasiah, J.; Kim, B.K.; Hillyer, C.D.; Strobert, E.A.; Orkin, J.L.; Swenson, R.B.; McClure, H.M.; Myers, L.A.; Saral, R.

Blood 84(1): 65-73

1994

ISSN/ISBN: 0006-4971
PMID: 8018931
DOI: 10.1182/blood.v84.1.65.65
Accession: 008544404
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Using a recently developed hepsulfam-induced pancytopenia model in rhesus macaques, we have studied the effects of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on marrow regeneration. Control animals were given hepsulfam (1.5 g/m-2 by a single 30-minute intravenous (IV) injection, n = 4), while study animals received hepsulfam followed by rhIL-6, rhIL-3, or a combination of rhIL-6 and rhIL-3 (n = 3 per study group).

PDF emailed within 0-6 h: $19.90




Related References

Clutterbuck, E.J.; Sanderson, C.J. 1990: Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor Blood 75(9): 1774-1779
Fujii, Y.; Imamura, M.; Hashino, S.; Kobayashi, H.; Kobayashi, M.; Kasai, M.; Sakurada, K.; Miyazaki, T. 1992: Therapy with cytokines and biological response modifiers brms prior to syngeneic bone marrow transplantation in mice effect of recombinant human interleukin 1 beta rhil 1 beta interleukin 2 rhil 2 interleukin 6 rhil 6 recombinant murine tumor necrosis factor alpha rmtnf alpha and chinese herbal medicine ninjin youei to nyt on immunohematologic reconstitution Biomedicine and Pharmacotherapy 46(5-7): 315
Gonter, P.W.; Hillyer, C.D.; Strobert, E.A.; Orkin, J.L.; Swenson, R.B.; Mcclure, H.M.; Myers, L.A.; Winton, E.F. 1993: The effect of varying ratios of administered rhIL-3 and rhGM-CSF on post-chemotherapy marrow regeneration in a nonhuman primate model Blood 82(10 Suppl 1): 365A
Gonter, P.W.; Hillyer, C.D.; Strobert, E.A.; Orkin, J.L.; Swenson, R.B.; Mcclure, H.M.; Myers, L.A.; Winton, E.F. 1993: Enhanced post-chemotherapy platelet and neutrophil recovery using combination rhIL-6 and rhGM-CSF or rhG-CSF in a nonhuman primate model Blood 82(10 Suppl 1): 365A
Modi M.; Nadeau R.; Ni Wu G.; Della Valle C.; Olejnik N.; Hayes T.; Liberato D. 1991: The pharmacokinetics of recombinant human interleukin 1 alpha rhil 1 alpha in rats that received single ascending intravenous doses of rhil 1 alpha and the resultant dose dependent concentrations of endogenous serum interleukin 6 il 6 FASEB Journal 5(6): A1567
Mumcuoglu, M.; Slavin, S. 1999: Enhancement of hematopoietic reconstitution with recombinant cytokines: effect of rhIL-6 in combination with rhGM-CSF and rhIL-3 on unmodified or T cell-depleted bone marrow Journal of HematoTherapy 8(3): 247-253
Aoki, I.; Homori, M.; Nakahara, K.; Higashi, K.; Ishikawa, K. 1995: Effects of rhIL-1 alpha, rhIL-1 beta, and rhIL-1 receptor antagonist on erythroid progenitors (CFU-E and BFU-E) in human bone marrow Experimental Hematology 23(3): 217-225
Mendoza, J.F.; López, R.; Weiss-Steider, B. 1991: Induction of Fc receptors and proliferative effect of recombinant human interleukins 1 and 2 (rhIL-1 and rhIL-2) on the leukemic lines WR19M.1 and WEHI3BD- Sangre 36(3): 205-209
Meden, H.; Fock, M.; Kuhn, W. 1994: Effect of recombinant human interleukin-3 (rhIL-3) on persisting chemotherapy-induced thrombocytopenia Anti-Cancer Drugs 5(4): 483-486
Grupp, S.A.; Bree, A.G.; Kaviani, M.D.; Schlerman, F.J.; Nagle, S.L.; Goldman, S.J. 1998: Synergystic effects of rhIL-11 and rhG-CSF on hematopoietic recovery after myelosuppressive chemotherapy in nonhuman primates Blood 92(10 Suppl 1 Part 1-2): 377A
Lazos, S.A.; Tsiftsoglou, A.S. 1998: Production and purification of recombinant human cytokines (rhIL-4, rhGM-CSF, and rhIL-1beta) from genetically engineered E. coli cells bearing pMAL expression vector constructs Journal of Protein Chemistry 17(6): 517
Rinehart, J.J.; Triozzi, P.L.; Lee, M.H.; Aldrich, W. 1990: The effect of intensive chemotherapy and recombinant human il 2 rhil 2 in a murine tumor model Proceedings of the American Association for Cancer Research Annual Meeting 31: 277
Gordon, M.S.; McCaskill-Stevens, W.J.; Battiato, L.A.; Loewy, J.; Loesch, D.; Breeden, E.; Hoffman, R.; Beach, K.J.; Kuca, B.; Kaye, J.; Sledge, G.W. 1996: A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy Blood 87(9): 3615-3624
Ryffel, B.; Weber, M. 1995: Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (Marmoset): Comparison with studies in rats Journal of Applied Toxicology: Jat 15(1): 19-26
Biesma B.; Pokorny R.; Kovarik J.M.; Willemse P.H.B.; De Vres E.G.E.; Duffy F. 1992: Pharmacokinetics of iv and sc recombinant human interleukin 3 rhil 3 Proceedings of the American Association for Cancer Research Annual Meeting 33: 242
Meden, H.; Fock, M.; Krauss, T.; Kuhn, W. 1999: Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia Zentralblatt für Gynakologie 121(8): 375-383
Ganser, A. 1990: Clinical application of recombinant human interleukin 3 rhil 3 Journal of Cancer Research and Clinical Oncology 116(Suppl Part 2): 875
Lee, E.; Min, H.-K.; Oskeritzian, C.A.; Kambe, N.; Schwartz, L.B.; Wook Chang, H. 2003: Recombinant human (rh) stem cell factor and rhIL-4 stimulate differentiation and proliferation of CD3+ cells from umbilical cord blood and CD3+ cells enhance FcepsilonR1 expression on fetal liver-derived mast cells in the presence of rhIL-4 Cellular Immunology 226(1): 30-36
Goldman, S.; Davenport, V.; Reaman, G.; Laver, J.; Kreissman, S.; Blazar, B.; Berg, S.; Kaye, J.; Patterson, F.; Cairo, M.S. 1997: Combination of rhIL-11+G-CSF enhances platelet and myeloid recovery following ifosfamide, carboplatin, and etoposide chemotherapy in children with solid tumors RhIL-11 is well tolerated at double the adult recommended dose Experimental Hematology 25(8): 786
Buckley, R.; Schiff, R.; Schiff, S.; Markert, L.; Gerber, P.; Paradise, C. 1989: Recombinant human interleukin 2 rhil 2 therapy in primary immunodeficiency Journal of Allergy and Clinical Immunology 83(1): 296